← Back to Search

68Ga-PSMA PET/CT for Prostate Cancer

Phase 3
Waitlist Available
Research Sponsored by Sir Mortimer B. Davis - Jewish General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Study Summary

This trial is studying the safety and effectiveness of using a PET scan to help guide decisions about prostate cancer treatment.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Efficacy of Ga68-PSMA PET/CT imaging as measured by sensitivity and specificity vs CT on a per lesion basis as compared to standard of truth
Efficacy of Ga68-PSMA PET/CT imaging as measured by sensitivity and specificity vs CT on a per patient basis as compared to standard of truth
Safety of Ga68-PSMA PET/CT imaging as measured by the incidence of adverse events (AE)

Trial Design

1Treatment groups
Experimental Treatment
Group I: 68Ga-PSMA PET/CTExperimental Treatment1 Intervention
68Ga-HBED-CC-PSMA PET/CT
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Gallium Ga-68 gozetotide
FDA approved

Find a Location

Who is running the clinical trial?

Sir Mortimer B. Davis - Jewish General HospitalLead Sponsor
55 Previous Clinical Trials
20,620 Total Patients Enrolled
14 Trials studying Prostate Cancer
3,139 Patients Enrolled for Prostate Cancer

Media Library

68Ga-HBED-CC-PSMA PET/CT Clinical Trial Eligibility Overview. Trial Name: NCT03001869 — Phase 3
Prostate Cancer Research Study Groups: 68Ga-PSMA PET/CT
Prostate Cancer Clinical Trial 2023: 68Ga-HBED-CC-PSMA PET/CT Highlights & Side Effects. Trial Name: NCT03001869 — Phase 3
68Ga-HBED-CC-PSMA PET/CT 2023 Treatment Timeline for Medical Study. Trial Name: NCT03001869 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

For whom is this research project meant?

"Researchers are looking for 1500 individuals with prostate cancer who meet the following eligibility criteria: between the ages of 18 and 120, diagnosed with prostate cancer, under a referring physician's care, resident of Canada, male sex, ECOG performance status 0-3 inclusive, able to understand and provide written informed consent, able to tolerate the physical/logistical requirements of a PET/CT scan including lying supine (or prone) for up to 40 minutes and tolerating intravenous cannulation."

Answered by AI

Are patients currently being accepted into this trial?

"Although this particular trial is no longer enrolling patients, according to the latest update on clinicaltrials.gov, there are 1377 other active trials that might be of interest."

Answered by AI

Are the requirements for this clinical study limited to those over 25 years old?

"To be eligible for this study, participants must be over 18 but not yet 120 years old."

Answered by AI

What medical condition does 68Ga-HBED-CC-PSMA PET/CT help to improve?

"68Ga-HBED-CC-PSMA PET/CT is most often used to target and treat tumor antigens. However, it can also be administered to patients with suspected metastasis, positron emission tomography, or prostate cancer."

Answered by AI

How many people are taking part in this clinical research project?

"Presently, this study is not seeking new participants. This trial was initially posted on July 1st, 2017 and last updated on October 24th, 2022. However, there are other medical trials that may be of interest; 1364 clinical trials for patients with prostate cancer and 68Ga-HBED-CC-PSMA PET/CT are actively enrolling right now."

Answered by AI

Could you please summarize what we know from prior research about 68Ga-HBED-CC-PSMA PET/CT?

"There are a total of 13 clinical trials studying 68Ga-HBED-CC-PSMA PET/CT. 1 of these is in Phase 3, while the rest are still gathering data. Most of these trials are based out of Brooklyn, New york but there are 17 total locations running these sorts of tests."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
68Ga-PSMA PET/CT in Prostate Cancer
Stephan Probst, MD 2017. "68Ga-PSMA PET/CT in Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03001869.
~69 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top